{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:09:50Z","timestamp":1793210990496,"version":"4.5.0"},"reference-count":92,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,17]],"date-time":"2018-05-17T00:00:00Z","timestamp":1526515200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","ashjournal.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Society of Hypertension"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.jash.2018.03.008","type":"journal-article","created":{"date-parts":[[2018,3,21]],"date-time":"2018-03-21T19:45:08Z","timestamp":1521661508000},"page":"409-425","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":203,"title":["Vascular toxicities with VEGF inhibitor therapies\u2013focus on hypertension and arterial thrombotic events"],"prefix":"10.1016","volume":"12","author":[{"given":"Rhian M.","family":"Touyz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra M.S.","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jash.2018.03.008_bib1","first-page":"1","article-title":"The growth of malignant disease in man and the lower animals, with special reference to the vascular system","volume":"1","author":"Goldmann","year":"1908","journal-title":"Proc R Soc Med"},{"key":"10.1016\/j.jash.2018.03.008_bib2","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor angiogenesis: therapeutic implications","volume":"285","author":"Folkman","year":"1971","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jash.2018.03.008_bib3","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/ncponc0403","article-title":"Lessons from phase III clinical trials on anti-VEGF therapy for cancer","volume":"3","author":"Jain","year":"2006","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1016\/j.jash.2018.03.008_bib4","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2217\/cns.14.31","article-title":"Antiangiogenic therapies for glioblastoma","volume":"3","author":"Arrillaga-Romany","year":"2014","journal-title":"CNS Oncol"},{"key":"10.1016\/j.jash.2018.03.008_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18102021","article-title":"Angiogenesis inhibitors in NSCLC","volume":"18","author":"Manzo","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.jash.2018.03.008_bib6","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3322\/caac.21411","article-title":"Treatment of renal cell carcinoma: current status and future directions","volume":"67","author":"Barata","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jash.2018.03.008_bib7","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s11912-009-0015-5","article-title":"VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy","volume":"11","author":"Cowey","year":"2009","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.jash.2018.03.008_bib8","doi-asserted-by":"crossref","first-page":"e000185","DOI":"10.1136\/esmoopen-2017-000185","article-title":"New treatment options for metastatic renal cell carcinoma","volume":"2","author":"Rodriguez-Vida","year":"2017","journal-title":"ESMO Open"},{"key":"10.1016\/j.jash.2018.03.008_bib9","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ejcsup.2013.07.016","article-title":"Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors","volume":"11","author":"Schmidinger","year":"2013","journal-title":"EJC Suppl"},{"key":"10.1016\/j.jash.2018.03.008_bib10","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1177\/1358863X14568705","article-title":"Approach to chemotherapy-associated thrombosis","volume":"20","author":"Oppelt","year":"2015","journal-title":"Vasc Med"},{"key":"10.1016\/j.jash.2018.03.008_bib11","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00280-004-0871-5","article-title":"A phase IB clinical and pharmacokinetic study of the angiogenesis inhibitor SU5416 and paclitaxel in recurrent or metastatic carcinoma of the head and neck","volume":"55","author":"Cooney","year":"2005","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.jash.2018.03.008_bib12","doi-asserted-by":"crossref","first-page":"4865","DOI":"10.1200\/JCO.2009.22.3875","article-title":"Thrombotic events in patients with cancer receiving antiangiogenesis agents","volume":"27","author":"Zangari","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jash.2018.03.008_bib13","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ctrv.2016.12.002","article-title":"Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: a systematic review and meta-analysis","volume":"53","author":"Abdel-Qadir","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jash.2018.03.008_bib14","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.cjca.2014.02.011","article-title":"Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors: understanding and managing a new syndrome","volume":"30","author":"Small","year":"2014","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jash.2018.03.008_bib15","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.semnephrol.2010.09.007","article-title":"Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker","volume":"30","author":"Robinson","year":"2010","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.jash.2018.03.008_bib16","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1161\/CIRCULATIONAHA.115.018347","article-title":"Vascular toxicities of cancer therapies: the old and the new\u2013an evolving avenue","volume":"133","author":"Herrmann","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jash.2018.03.008_bib17","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/annonc\/mdn713","article-title":"Management of hypertension in angiogenesis inhibitor-treated patients","volume":"20","author":"Izzedine","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jash.2018.03.008_bib18","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1634\/theoncologist.2010-0002","article-title":"An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activity","volume":"16","author":"Mir","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.jash.2018.03.008_bib19","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1056\/NEJMc072330","article-title":"Home blood-pressure monitoring in patients receiving sunitinib","volume":"358","author":"Azizi","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jash.2018.03.008_bib20","doi-asserted-by":"crossref","first-page":"6250","DOI":"10.1158\/1078-0432.CCR-09-0058","article-title":"Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment","volume":"15","author":"Maitland","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jash.2018.03.008_bib21","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2215\/CJN.08111109","article-title":"Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor","volume":"5","author":"Robinson","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jash.2018.03.008_bib22","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/cncr.28972","article-title":"Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway","volume":"121","author":"Hamnvik","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.jash.2018.03.008_bib23","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1161\/HYPERTENSIONAHA.115.05435","article-title":"Greater sensitivity of blood pressure than renal toxicity to tyrosine kinase receptor inhibition with sunitinib","volume":"66","author":"Lankhorst","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.jash.2018.03.008_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17122073","article-title":"Influence of tyrosine kinase inhibitors on hypertension and nephrotoxicity in metastatic renal cell cancer patients","volume":"17","author":"Semeniuk-Wojtas","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jash.2018.03.008_bib25","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/jnci\/djr128","article-title":"Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib","volume":"103","author":"Rini","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jash.2018.03.008_bib26","first-page":"4123","article-title":"VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma","volume":"62","author":"Bates","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.jash.2018.03.008_bib27","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/nrc2505","article-title":"VEGF-A splicing: the key to anti-angiogenic therapeutics?","volume":"8","author":"Harper","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jash.2018.03.008_bib28","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.2174\/138945010791591395","article-title":"Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy","volume":"11","author":"Niu","year":"2010","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.jash.2018.03.008_bib29","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1038\/sj.bjc.6604309","article-title":"The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice","volume":"98","author":"Rennel","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jash.2018.03.008_bib30","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1161\/01.ATV.17.11.2793","article-title":"Vascular endothelial growth factor\/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium","volume":"17","author":"Horowitz","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jash.2018.03.008_bib31","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1161\/HYPERTENSIONAHA.109.129973","article-title":"Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression","volume":"54","author":"Facemire","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.jash.2018.03.008_bib32","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1161\/HYPERTENSIONAHA.110.160481","article-title":"Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors","volume":"56","author":"Robinson","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.jash.2018.03.008_bib33","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1161\/HYPERTENSIONAHA.111.00841","article-title":"Role of endogenous vascular endothelial growth factor in endothelium-dependent vasodilation in humans","volume":"61","author":"Thijs","year":"2013","journal-title":"Hypertension"},{"key":"10.1016\/j.jash.2018.03.008_bib34","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1097\/HJH.0000000000000662","article-title":"Impaired endothelium-dependent vasodilation does not initiate the development of sunitinib-associated hypertension","volume":"33","author":"Thijs","year":"2015","journal-title":"J Hypertens"},{"key":"10.1016\/j.jash.2018.03.008_bib35","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1158\/1078-0432.CCR-07-5050","article-title":"Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor","volume":"14","author":"Steeghs","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jash.2018.03.008_bib36","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1161\/HYPERTENSIONAHA.110.168120","article-title":"Contrary effects of the receptor tyrosine kinase inhibitor vandetanib on constitutive and flow-stimulated nitric oxide elaboration in humans","volume":"58","author":"Mayer","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.jash.2018.03.008_bib37","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s10549-013-2632-9","article-title":"A phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer","volume":"140","author":"Mayer","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jash.2018.03.008_bib38","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/annonc\/mdp417","article-title":"Reversibility of capillary density after discontinuation of bevacizumab treatment","volume":"21","author":"Steeghs","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jash.2018.03.008_bib39","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1161\/HYPERTENSIONAHA.111.182220","article-title":"Sunitinib-induced systemic vasoconstriction in swine is endothelin mediated and does not involve nitric oxide or oxidative stress","volume":"59","author":"Kappers","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.jash.2018.03.008_bib40","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1161\/HYPERTENSIONAHA.109.149690","article-title":"Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels","volume":"56","author":"Kappers","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.jash.2018.03.008_bib41","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1161\/01.HYP.30.1.22","article-title":"Endogenous endothelin modulates blood pressure, plasma volume, and albumin escape after systemic nitric oxide blockade","volume":"30","author":"Filep","year":"1997","journal-title":"Hypertension"},{"issue":"4","key":"10.1016\/j.jash.2018.03.008_bib42","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1161\/HYPERTENSIONAHA.117.10490","article-title":"VEGFR (vascular endothelial growth factor receptor) inhibition induces cardiovascular damage via redox-sensitive processes","volume":"71","author":"Neves","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.jash.2018.03.008_bib43","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/jnci\/djq091","article-title":"Panel CbtATFotNCIIDSC. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors","volume":"102","author":"Maitland","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jash.2018.03.008_bib44","doi-asserted-by":"crossref","first-page":"6152","DOI":"10.1200\/JCO.2009.22.2273","article-title":"Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of cediranib in patients with advanced solid tumors","volume":"27","author":"Langenberg","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jash.2018.03.008_bib45","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"Group","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jash.2018.03.008_bib46","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1161\/HYP.0000000000000065","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.jash.2018.03.008_bib47","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1002\/cncr.29169","article-title":"Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on cancer and leukemia group B (CALGB) 90401 (alliance)","volume":"121","author":"Patel","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.jash.2018.03.008_bib48","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1093\/jnci\/djm086","article-title":"Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab","volume":"99","author":"Scappaticci","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jash.2018.03.008_bib49","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1177\/1078155216679025","article-title":"Evaluation of thromboembolic events in cancer patients receiving bevacizumab according to the Japanese adverse drug event report database","volume":"24","author":"Matsumura","year":"2018","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.jash.2018.03.008_bib50","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1200\/JCO.2009.27.2757","article-title":"Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials","volume":"28","author":"Choueiri","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jash.2018.03.008_bib51","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1001\/jama.2016.7050","article-title":"Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged \u226575 years: a randomized clinical trial","volume":"315","author":"Williamson","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jash.2018.03.008_bib52","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/ajh\/hpt201","article-title":"Vascular endothelial growth factor inhibitor-induced hypertension: from pathophysiology to prevention and treatment based on long-acting nitric oxide donors","volume":"27","author":"Kruzliak","year":"2014","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.jash.2018.03.008_bib53","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.1158\/1078-0432.CCR-07-4783","article-title":"Inhibition of vascular endothelial growth factor-a signaling induces hypertension: examining the effect of cediranib (recentin; AZD2171) treatment on blood pressure in rat and the use of concomitant antihypertensive therapy","volume":"14","author":"Curwen","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jash.2018.03.008_bib54","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1161\/HYPERTENSIONAHA.114.04187","article-title":"Treatment of hypertension and renal injury induced by the angiogenesis inhibitor sunitinib: preclinical study","volume":"64","author":"Lankhorst","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.jash.2018.03.008_bib55","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1067\/mhj.2000.110093","article-title":"Carvedilol improves endothelium-dependent dilatation in patients with coronary artery disease","volume":"140","author":"Matsuda","year":"2000","journal-title":"Am Heart J"},{"key":"10.1016\/j.jash.2018.03.008_bib56","doi-asserted-by":"crossref","first-page":"579","DOI":"10.2165\/00003495-200868050-00002","article-title":"Beta-blockers and coronary flow reserve: the importance of a vasodilatory action","volume":"68","author":"Galderisi","year":"2008","journal-title":"Drugs"},{"key":"10.1016\/j.jash.2018.03.008_bib57","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1038\/bjc.2013.205","article-title":"Beta-blockers increase response to chemotherapy via direct antitumour and anti-angiogenic mechanisms in neuroblastoma","volume":"108","author":"Pasquier","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jash.2018.03.008_bib58","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1016\/j.ejca.2011.04.019","article-title":"Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination","volume":"47","author":"Keizman","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jash.2018.03.008_bib59","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1093\/annonc\/mdv147","article-title":"Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma","volume":"26","author":"Izzedine","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jash.2018.03.008_bib60","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1158\/1078-0432.CCR-14-2332","article-title":"Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma","volume":"21","author":"McKay","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jash.2018.03.008_bib61","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1245\/s10434-015-4436-0","article-title":"Prognostic impact of renin-angiotensin system blockade on renal cell carcinoma after surgery","volume":"22","author":"Miyajima","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jash.2018.03.008_bib62","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1002\/ijc.29972","article-title":"Angiotensin system inhibitors and survival in patients with metastatic renal cell carcinoma treated with VEGF-targeted therapy: a pooled secondary analysis of clinical trials","volume":"138","author":"Sorich","year":"2016","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jash.2018.03.008_bib63","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3109\/02841860903524396","article-title":"Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials","volume":"49","author":"Ranpura","year":"2010","journal-title":"Acta Oncol"},{"key":"10.1016\/j.jash.2018.03.008_bib64","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1093\/annonc\/mdq587","article-title":"Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes","volume":"22","author":"Schutz","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jash.2018.03.008_bib65","doi-asserted-by":"crossref","first-page":"e66721","DOI":"10.1371\/journal.pone.0066721","article-title":"Angiogenesis inhibitor bevacizumab increases the risk of ischemic heart disease associated with chemotherapy: a meta-analysis","volume":"8","author":"Chen","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jash.2018.03.008_bib66","doi-asserted-by":"crossref","first-page":"e102484","DOI":"10.1371\/journal.pone.0102484","article-title":"Increased risk of cerebrovascular events in patients with cancer treated with bevacizumab: a meta-analysis","volume":"9","author":"Zuo","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jash.2018.03.008_bib67","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.critrevonc.2014.04.004","article-title":"Risk of arterial thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: an up-to-date meta-analysis","volume":"92","author":"Qi","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.jash.2018.03.008_bib68","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1067\/mnc.2001.114148","article-title":"The endothelium: dysfunction and beyond","volume":"8","author":"Herrmann","year":"2001","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.jash.2018.03.008_bib69","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1161\/CIRCULATIONAHA.111.037283","article-title":"Mechanisms of coronary artery spasm","volume":"124","author":"Lanza","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jash.2018.03.008_bib70","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jjcc.2009.03.009","article-title":"Sorafenib-induced acute myocardial infarction due to coronary artery spasm","volume":"54","author":"Arima","year":"2009","journal-title":"J Cardiol"},{"key":"10.1016\/j.jash.2018.03.008_bib71","doi-asserted-by":"crossref","first-page":"187ra69","DOI":"10.1126\/scitranslmed.3005066","article-title":"Coronary microvascular pericytes are the cellular target of sunitinib malate-induced cardiotoxicity","volume":"5","author":"Chintalgattu","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jash.2018.03.008_bib72","first-page":"775","article-title":"Impaired coronary flow reserve in metastatic cancer patients treated with sunitinib","volume":"18","author":"Sen","year":"2013","journal-title":"J BUON"},{"key":"10.1016\/j.jash.2018.03.008_bib73","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0021-9150(03)00299-5","article-title":"Statins differentially regulate vascular endothelial growth factor synthesis in endothelial and vascular smooth muscle cells","volume":"170","author":"Frick","year":"2003","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jash.2018.03.008_bib74","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1016\/j.ijcard.2013.03.010","article-title":"Systemic VEGF inhibition accelerates experimental atherosclerosis and disrupts endothelial homeostasis\u2013implications for cardiovascular safety","volume":"168","author":"Winnik","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jash.2018.03.008_bib75","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/1471-2407-12-231","article-title":"Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib","volume":"12","author":"Pantaleo","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jash.2018.03.008_bib76","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1007\/s10637-010-9500-9","article-title":"VEGF pathway inhibition by anticancer agent sunitinib and susceptibility to atherosclerosis plaque disruption","volume":"29","author":"Ropert","year":"2011","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.jash.2018.03.008_bib77","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/ajh.21277","article-title":"Hemostatic complications of angiogenesis inhibitors in cancer patients","volume":"83","author":"Elice","year":"2008","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jash.2018.03.008_bib78","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1161\/01.ATV.0000030186.66672.36","article-title":"Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor\/vascular endothelial growth factor receptor pathway in cancer patients","volume":"22","author":"Kuenen","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jash.2018.03.008_bib79","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1538-7836.2008.03212.x","article-title":"Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice","volume":"7","author":"Meyer","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jash.2018.03.008_bib80","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ahj.2011.10.018","article-title":"Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors","volume":"163","author":"Steingart","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.jash.2018.03.008_bib81","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S1470-2045(09)70222-0","article-title":"Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials","volume":"10","author":"Je","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jash.2018.03.008_bib82","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.cell.2007.06.054","article-title":"Autocrine VEGF signaling is required for vascular homeostasis","volume":"130","author":"Lee","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.jash.2018.03.008_bib83","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1161\/01.RES.0000014081.30867.F8","article-title":"Double-edged role of statins in angiogenesis signaling","volume":"90","author":"Urbich","year":"2002","journal-title":"Circ Res"},{"key":"10.1016\/j.jash.2018.03.008_bib84","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/ijc.24760","article-title":"In\u00a0vivo evidence of duality effects for lovastatin in a nude mouse cancer model","volume":"126","author":"Wang","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jash.2018.03.008_bib85","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.3892\/ijo.2013.1833","article-title":"Endothelial NO synthase and reactive oxygen species mediated effect of simvastatin on vessel structure and function: pleiotropic and dose-dependent effect on tumor vascular stabilization","volume":"42","author":"Chen","year":"2013","journal-title":"Int J Oncol"},{"key":"10.1016\/j.jash.2018.03.008_bib86","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1001\/jama.292.18.2217","article-title":"Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial","volume":"292","author":"Nissen","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.jash.2018.03.008_bib87","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1161\/01.ATV.16.3.425","article-title":"Evidence for a synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis in symptomatic patients with normal to moderately raised cholesterol levels. The REGRESS Study Group","volume":"16","author":"Jukema","year":"1996","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jash.2018.03.008_bib88","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1517\/14656566.5.2.459","article-title":"Amlodipine and atorvastatin in atherosclerosis: a review of the potential of combination therapy","volume":"5","author":"Jukema","year":"2004","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jash.2018.03.008_bib89","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJM200002173420702","article-title":"Effect of exercise on coronary endothelial function in patients with coronary artery disease","volume":"342","author":"Hambrecht","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jash.2018.03.008_bib90","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1161\/01.CIR.0000121360.31954.1F","article-title":"Percutaneous coronary angioplasty compared with exercise training in patients with stable coronary artery disease: a randomized trial","volume":"109","author":"Hambrecht","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jash.2018.03.008_bib91","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1177\/1741826711403068","article-title":"Exercise training restores the endothelial response to vascular growth factors in patients with stable coronary artery disease","volume":"19","author":"Beck","year":"2012","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jash.2018.03.008_bib92","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jcmg.2015.02.012","article-title":"Healing after myocardial infarction: a loosely defined process","volume":"8","author":"Arai","year":"2015","journal-title":"JACC Cardiovasc Imaging"}],"container-title":["Journal of the American Society of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933171118300767?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933171118300767?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,22]],"date-time":"2018-08-22T22:53:31Z","timestamp":1534978411000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933171118300767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":92,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S1933171118300767"],"URL":"https:\/\/doi.org\/10.1016\/j.jash.2018.03.008","relation":{},"ISSN":["1933-1711"],"issn-type":[{"value":"1933-1711","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vascular toxicities with VEGF inhibitor therapies\u2013focus on hypertension and arterial thrombotic events","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Society of Hypertension","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jash.2018.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc. on behalf of American Society of Hypertension.","name":"copyright","label":"Copyright"}]}}